J&J quietly punts a pair of early-stage bispecifics for solid tumors
Johnson & Johnson has put two early-stage bispecific antibodies on the backburner, the pharma giant revealed as part of its quarterly update.
Listed in the pipeline as recently as October, JNJ-6358 — a bispecific antibody binding to CD3 on T cells and human leukocyte antigen G (HLA-G) on cancer cells — and JNJ-8902 — a CD3 x TMEFF2 bispecific — were nowhere to be found in the latest pipeline presentation.
A spokesperson confirmed that while their respective trials are ongoing, these “are not prioritized assets in our development portfolio.” FierceBiotech first noted the pipeline cuts.
Both of the Phase I trials are active but not recruiting, the spokesperson added.
Records on clinicaltrials.gov suggested both trials ended up enrolling fewer patients than expected.
The study for JNJ-6358 targeted patients with renal cell carcinoma, ovarian cancer, colorectal cancer and other advanced solid tumors. A total of 39 patients were enrolled before recruitment stopped, compared to 140 originally anticipated.
In the other trial, investigators enrolled 82 men with metastatic castration-resistant prostate cancer to receive JNJ-8902 — but scrapped the original 120 goal.
Multiple early-stage programs targeting prostate cancer remain in J&J’s pipeline, as well as an experimental therapy for colorectal cancer, among others.